University of Manitoba


Update Clinical Trials for my Centre
University of Manitoba
Open Trial Description
NCIC Protocol number
IND. 138
Randomized Phase II study of NX 211 given by two different intravenous schedules in advanced and/or recurrent epithelial ovarian cancer
NCIC Protocol number
OV 13 EORTC 55971
Randomized Phase III study comparing upfront debulking surgery versus neoadjuvant chemotherapy in patients with Stage IIIC or IV epithelial ovarian cancer
NCIC Protocol Number
OV 14 EORTC 55981
Randomized Phase III study of paclitaxel/epirubicin/carboplatinum (TEC) versus paclitaxel/carboplatinum (TC) in the treatment of patients with advanced ovarian cancer
OVA-Gy-15 A multicentre clinical trial of intravenous OvaRexTM Mab-B43.13 as post chemotherapy consolidation for ovarian. Tubal and peritoneal carcinoma.
PALO-99-04 A double-blind clinical trial to compare single IV doses of palonestron, 0.25 mg or 0.75 mg. and dolasetron, 100 mg IV, in the prevention of moderately emetogenic chemotherapy-induced nausea and vomiting.
PALO-99-05 A double-blind clinical trail to compare single IV doses of palonosetron, 0.25 mg or 0.75 mg. and ondansetron, 32 mg. IV, in the prevention of highly emetogenic chemotherapy-induced nausea and vomiting
PALO-99-06 A mulicenter, open-label study to assess the safety and efficacy of IV palonosetron for the prevention of chemotherapy-induced nausea and vomiting in repeated chemotherapy cycles.